Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

153.58USD
18 Sep 2018
Change (% chg)

$1.23 (+0.81%)
Prev Close
$152.35
Open
$153.02
Day's High
$155.53
Day's Low
$150.32
Volume
266,433
Avg. Vol
435,299
52-wk High
$176.44
52-wk Low
$42.97

Select another date:

Tue, Jun 19 2018

Sarepta shares soar as Duchenne gene therapy shows promise

Sarepta Therapeutics' shares jumped 60 percent on Tuesday after promising results from a gene therapy study positioned the specialty drugmaker as a potential leader in the market for Duchenne muscular dystrophy (DMD) treatments.

UPDATE 3-Sarepta shares soar as Duchenne gene therapy shows promise

* Sarepta shares rise as much as 67.7 percent (Adds details on study results, updates share price)

BRIEF-Sarepta And Invitae Expand Partnership To Advance Clinical Research In Duchenne Muscular Dystrophy

* SAREPTA AND INVITAE EXPAND PARTNERSHIP TO ADVANCE CLINICAL RESEARCH IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage:

BRIEF-Sarepta Therapeutics Reports Q1 Loss Per Share Of $0.28

* SAREPTA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

BRIEF-Sarepta Therapeutics Announces Partnership With Myonexus Therapeutics

* SAREPTA THERAPEUTICS ANNOUNCES PARTNERSHIP WITH MYONEXUS THERAPEUTICS FOR THE ADVANCEMENT OF MULTIPLE GENE THERAPY PROGRAMS AIMED AT TREATING DISTINCT FORMS OF LIMB-GIRDLE MUSCULAR DYSTROPHIES

BRIEF-Sarepta Therapeutics Inc Says CEO Douglas Ingram's 2017 Total Compensation Was $56.9 Million

* SAREPTA THERAPEUTICS INC SAYS CEO DOUGLAS INGRAM'S 2017 TOTAL COMPENSATION WAS $56.9 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2I3lSGe) Further company coverage:

Sarepta Therapeutics beats bid to revive shareholder class action

A federal appeals court has upheld the dismissal of a lawsuit accusing Sarepta Therapeutics Inc of misleading shareholders by suggesting it had gathered enough data to seek U.S. Food and Drug Administration approval in 2014 to market a treatment for a rare muscle disorder.

Select another date: